Considering that low RKIP levels are associated with worse patients’ prognosis, a hypothetical scenario includes RKIP-targeted therapies being more effective in cancer types such as ACC and LIHC because of the existing higher levels of RKIP as compared to others. The gene discussed is PEBP1; the disease is cancer.